AKT1 and gastrointestinal stromal tumor: We have previously shown that targeting the KIT signaling pathway vertically at different nodes (i.e., at KIT using IM, in combination with downstream inhibition of AKT) demonstrated significant efficacy in an IM-sensitive GIST model.